サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1239485

医療用バイオミメティクス市場：疾患タイプ別（心臓血管、整形外科、眼科、歯科、その他）、アプリケーション別（創傷治癒、組織工学、ドラッグデリバリー、その他）、世界の機会分析と産業予測、2021年～2031年

Medical Biomimetics Market By Disease Type (Cardiovascular, Orthopedic, Ophthalmology, Dental, Others), By Application (Wound Healing, Tissue Engineering, Drug Delivery, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 221 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
医療用バイオミメティクス市場：疾患タイプ別（心臓血管、整形外科、眼科、歯科、その他）、アプリケーション別（創傷治癒、組織工学、ドラッグデリバリー、その他）、世界の機会分析と産業予測、2021年～2031年
出版日: 2023年01月01日
発行: Allied Market Research
ページ情報: 英文 221 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

医療用バイオミメティクスの世界市場規模は、2021年に354億米ドルとなり、2022年から2031年にかけてCAGR7.2%で成長し、2031年には689億米ドルに達すると予測されています。

バイオミメティクスは、自然界に存在する側面やプロセスを利用して、人間の困難な問題を解決する最先端の設計思想です。バイオミメティクス」という言葉は、古代ギリシャ語の「bios」と「mimesis」という2つの単語から成り、それぞれ「生命」と「模倣」と訳されています。医療用バイオミメティクスは、健康に関わる人間の複雑な問題を解決するために、自然からインスピレーションを得る装置です。バイオミメティクスは、創傷治癒、組織工学、ドラッグデリバリーなどに利用されています。バイオミメティック材料は、歯の治療や保存、心臓の再生、自然な能力の強化＆手足の機能回復に使用することができます。

医療用バイオミメティクス市場の成長を促進する主な要因には、薬物の標的送達のためのバイオミメティクスに基づくナノカプセル/ナノスフェア、ナノクリスタル、リポソーム、ナノ脂質キャリア/固体脂質ナノ粒子、ナノスポンジ、デンドリマーの使用など、ドラッグデリバリーの技術進歩の増加が含まれます。例えば、2022年11月に発表された総説「細胞膜被覆ナノ粒子：新規多機能バイオミメティックドラッグデリバリーシステム」によると、細胞膜表面タンパク質の生物学的役割は、ナノ粒子に免疫逃避、長い循環時間、標的送達などの機能を付与するため、これらのタンパク質はドラッグデリバリーの分野で広く使用されています。同じソースによると、バイオミメティックアプローチでは、マクロファージの取り込みと全身クリアランスを減らすために、赤血球膜がポリマーナノ粒子のコーティングに使用されているとのことです。

さらに、心疾患の急増は、LifeMatrix組織などの次世代インプラントとして、人間の代替組織を成長させる生体工学技術の需要を促進し、医療用バイオミメティクス市場の成長を牽引しています。例えば、疾病管理予防センター（CDC）2022によると、米国では2020年に約697,000人が心臓病で死亡しています。同じソースによると、毎年、米国では約805,000人が心臓発作を起こしています。この805,000人のうち、605,000人が初めて心臓発作を起こし、200,000人がすでに心臓発作を起こしている人に起こっています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
    • 供給企業の交渉力が低い
    • 買い手の交渉力
    • 代替品の脅威が低い
    • 新規参入業者の脅威が低い
    • 適度な競争の激しさ
  • 市場力学
    • 促進要因
      • 慢性創傷の有病率と発生率の上昇
      • 歯科疾患の有病率の上昇
      • 心臓病の有病率の上昇
    • 抑制要因
      • 厳格な規制規則と高い生産単価
    • 機会
      • 研究開発と製品発売の増加
  • 市場におけるCOVID-19影響分析

第4章 医療用バイオミメティクス市場：疾患の種類別

  • 概要
    • 市場規模と予測
  • 心臓血管
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 整形外科
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 眼科
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • 歯科
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • その他
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第5章 医療用バイオミメティクス市場：アプリケーション別

  • 概要
    • 市場規模と予測
  • 創傷治癒
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • ヒト組織工学
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • ドラッグデリバリー
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別
  • その他
    • 主要な市場動向、成長要因と機会
    • 市場規模と予測：地域別
    • 市場シェア分析： 国別

第6章 医療用バイオミメティクス市場：地域別

  • 概要
    • 市場規模と予測：地域別
  • 北米
    • 主な動向と機会
    • 市場規模と予測：疾患別
    • 市場規模と予測：用途別
    • 市場規模と予測：国別
      • 米国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • カナダ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • メキシコ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
  • 欧州
    • 主な動向と機会
    • 市場規模と予測：疾患別
    • 市場規模と予測：用途別
    • 市場規模と予測：国別
      • ドイツ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • フランス
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • 英国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • イタリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • スペイン
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • その他欧州
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
  • アジア太平洋
    • 主な動向と機会
    • 市場規模と予測：疾患別
    • 市場規模と予測：用途別
    • 市場規模と予測：国別
      • 中国
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • 日本
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • インド
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • オーストラリア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • その他アジア太平洋地域
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
  • ラテンアメリカ・中東・アフリカ
    • 主な動向と機会
    • 市場規模と予測：疾患別
    • 市場規模と予測：用途別
    • 市場規模と予測：国別
      • ブラジル
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • サウジアラビア
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • 南アフリカ
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別
      • ラテンアメリカ・中東・アフリカの残り
      • 主要な市場動向、成長要因と機会
      • 市場規模と予測：疾患別
      • 市場規模と予測：用途別

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要企業10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2021

第8章 企業プロファイル

  • Otsuka Medical Devices Co., Ltd.
  • AVINENT Science and Technology
  • CorNeat Vision
  • Swedish Biomimetics 3000 ApS
  • Osteopore International Pte Ltd
  • Curasan, inc.
  • Keystone Dental Group
  • Zimmer Biomet Holding Inc.
  • Biohorizons
  • Blatchford Limited
図表

LIST OF TABLES

  • TABLE 01. GLOBAL MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. MEDICAL BIOMIMETICS MARKET FOR CARDIOVASCULAR, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. MEDICAL BIOMIMETICS MARKET FOR ORTHOPEDIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. MEDICAL BIOMIMETICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. MEDICAL BIOMIMETICS MARKET FOR DENTAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. MEDICAL BIOMIMETICS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. GLOBAL MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. MEDICAL BIOMIMETICS MARKET FOR WOUND HEALING, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. MEDICAL BIOMIMETICS MARKET FOR TISSUE ENGINEERING, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. MEDICAL BIOMIMETICS MARKET FOR DRUG DELIVERY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. MEDICAL BIOMIMETICS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. MEDICAL BIOMIMETICS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. NORTH AMERICA MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. NORTH AMERICA MEDICAL BIOMIMETICS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. U.S. MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. U.S. MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. CANADA MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. CANADA MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. MEXICO MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. MEXICO MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. EUROPE MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. EUROPE MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. EUROPE MEDICAL BIOMIMETICS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. GERMANY MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. GERMANY MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. FRANCE MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. FRANCE MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. UK MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. UK MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. ITALY MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. ITALY MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. SPAIN MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. SPAIN MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. REST OF EUROPE MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. REST OF EUROPE MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. ASIA-PACIFIC MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. ASIA-PACIFIC MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. ASIA-PACIFIC MEDICAL BIOMIMETICS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. CHINA MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. CHINA MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. JAPAN MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. JAPAN MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. INDIA MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. INDIA MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. AUSTRALIA MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. AUSTRALIA MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. LAMEA MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. LAMEA MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. LAMEA MEDICAL BIOMIMETICS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. BRAZIL MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. BRAZIL MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. SAUDI ARABIA MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. SAUDI ARABIA MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. SOUTH AFRICA MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. SOUTH AFRICA MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. REST OF LAMEA MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. REST OF LAMEA MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. OTSUKA MEDICAL DEVICES CO., LTD.: KEY EXECUTIVES
  • TABLE 62. OTSUKA MEDICAL DEVICES CO., LTD.: COMPANY SNAPSHOT
  • TABLE 63. OTSUKA MEDICAL DEVICES CO., LTD.: PRODUCT SEGMENTS
  • TABLE 64. OTSUKA MEDICAL DEVICES CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 65. OTSUKA MEDICAL DEVICES CO., LTD.: KEY STRATERGIES
  • TABLE 66. AVINENT SCIENCE AND TECHNOLOGY: KEY EXECUTIVES
  • TABLE 67. AVINENT SCIENCE AND TECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 68. AVINENT SCIENCE AND TECHNOLOGY: PRODUCT SEGMENTS
  • TABLE 69. AVINENT SCIENCE AND TECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 70. CORNEAT VISION: KEY EXECUTIVES
  • TABLE 71. CORNEAT VISION: COMPANY SNAPSHOT
  • TABLE 72. CORNEAT VISION: PRODUCT SEGMENTS
  • TABLE 73. CORNEAT VISION: PRODUCT PORTFOLIO
  • TABLE 74. CORNEAT VISION: KEY STRATERGIES
  • TABLE 75. SWEDISH BIOMIMETICS 3000 APS: KEY EXECUTIVES
  • TABLE 76. SWEDISH BIOMIMETICS 3000 APS: COMPANY SNAPSHOT
  • TABLE 77. SWEDISH BIOMIMETICS 3000 APS: PRODUCT SEGMENTS
  • TABLE 78. SWEDISH BIOMIMETICS 3000 APS: PRODUCT PORTFOLIO
  • TABLE 79. OSTEOPORE INTERNATIONAL PTE LTD: KEY EXECUTIVES
  • TABLE 80. OSTEOPORE INTERNATIONAL PTE LTD: COMPANY SNAPSHOT
  • TABLE 81. OSTEOPORE INTERNATIONAL PTE LTD: PRODUCT SEGMENTS
  • TABLE 82. OSTEOPORE INTERNATIONAL PTE LTD: PRODUCT PORTFOLIO
  • TABLE 83. OSTEOPORE INTERNATIONAL PTE LTD: KEY STRATERGIES
  • TABLE 84. CURASAN, INC.: KEY EXECUTIVES
  • TABLE 85. CURASAN, INC.: COMPANY SNAPSHOT
  • TABLE 86. CURASAN, INC.: PRODUCT SEGMENTS
  • TABLE 87. CURASAN, INC.: PRODUCT PORTFOLIO
  • TABLE 88. KEYSTONE DENTAL GROUP: KEY EXECUTIVES
  • TABLE 89. KEYSTONE DENTAL GROUP: COMPANY SNAPSHOT
  • TABLE 90. KEYSTONE DENTAL GROUP: PRODUCT SEGMENTS
  • TABLE 91. KEYSTONE DENTAL GROUP: PRODUCT PORTFOLIO
  • TABLE 92. KEYSTONE DENTAL GROUP: KEY STRATERGIES
  • TABLE 93. ZIMMER BIOMET HOLDING INC.: KEY EXECUTIVES
  • TABLE 94. ZIMMER BIOMET HOLDING INC.: COMPANY SNAPSHOT
  • TABLE 95. ZIMMER BIOMET HOLDING INC.: PRODUCT SEGMENTS
  • TABLE 96. ZIMMER BIOMET HOLDING INC.: PRODUCT PORTFOLIO
  • TABLE 97. BIOHORIZONS: KEY EXECUTIVES
  • TABLE 98. BIOHORIZONS: COMPANY SNAPSHOT
  • TABLE 99. BIOHORIZONS: PRODUCT SEGMENTS
  • TABLE 100. BIOHORIZONS: PRODUCT PORTFOLIO
  • TABLE 101. BLATCHFORD LIMITED: KEY EXECUTIVES
  • TABLE 102. BLATCHFORD LIMITED: COMPANY SNAPSHOT
  • TABLE 103. BLATCHFORD LIMITED: PRODUCT SEGMENTS
  • TABLE 104. BLATCHFORD LIMITED: PRODUCT PORTFOLIO
  • TABLE 105. BLATCHFORD LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. MEDICAL BIOMIMETICS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF MEDICAL BIOMIMETICS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN MEDICAL BIOMIMETICS MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMEDICAL BIOMIMETICS MARKET
  • FIGURE 10. MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MEDICAL BIOMIMETICS MARKET FOR CARDIOVASCULAR, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MEDICAL BIOMIMETICS MARKET FOR ORTHOPEDIC, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MEDICAL BIOMIMETICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MEDICAL BIOMIMETICS MARKET FOR DENTAL, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MEDICAL BIOMIMETICS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 16. MEDICAL BIOMIMETICS MARKET, BY APPLICATION, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MEDICAL BIOMIMETICS MARKET FOR WOUND HEALING, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MEDICAL BIOMIMETICS MARKET FOR TISSUE ENGINEERING, BY COUNTRY 2021-2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MEDICAL BIOMIMETICS MARKET FOR DRUG DELIVERY, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MEDICAL BIOMIMETICS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 21. MEDICAL BIOMIMETICS MARKET BY REGION, 2021
  • FIGURE 22. U.S. MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 23. CANADA MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. MEXICO MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. GERMANY MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. FRANCE MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. UK MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. ITALY MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. SPAIN MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. REST OF EUROPE MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. CHINA MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. INDIA MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. AUSTRALIA MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. REST OF ASIA-PACIFIC MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. BRAZIL MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. SAUDI ARABIA MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. SOUTH AFRICA MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. REST OF LAMEA MEDICAL BIOMIMETICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 44. COMPETITIVE DASHBOARD
  • FIGURE 45. COMPETITIVE HEATMAP: MEDICAL BIOMIMETICS MARKET
  • FIGURE 46. TOP PLAYER POSITIONING, 2021
  • FIGURE 47. OTSUKA MEDICAL DEVICES CO., LTD.: NET REVENUE, 2019-2021 ($BILLION)
  • FIGURE 48. OTSUKA MEDICAL DEVICES CO., LTD.: RESEARCH & DEVELOPMENT EXPENDITURE, 2019-2021 ($BILLION)
  • FIGURE 49. OTSUKA MEDICAL DEVICES CO., LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 50. OSTEOPORE INTERNATIONAL PTE LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 51. OSTEOPORE INTERNATIONAL PTE LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. ZIMMER BIOMET HOLDING INC.: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 53. ZIMMER BIOMET HOLDING INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 54. ZIMMER BIOMET HOLDING INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
目次
Product Code: A10865

The global medical biomimetics market size was valued at $35.4 billion in 2021 and is projected to reach $68.9 billion by 2031, growing at a CAGR of 7.2% from 2022 to 2031. Biomimetics is a cutting-edge design idea that uses aspects and processes found in nature to solve challenging human problems. The term "biomimetics" consists of the two ancient Greek words i.e., "bios" and "mimesis," which translate to "life" and "imitate," respectively. Medical biomimetics is a device that draws inspiration from nature to solve complex human problems related to health. Biomimetics is used for wound healing, tissue engineering, and drug delivery. Biomimetic materials can be used to treat and preserve the tooth, cardiac regeneration, enhance natural abilities & restore the function of limbs.

Major factors driving the growth of the medical biomimetics market include a rise in technological advancement in drug delivery, such as the use of nanocapsules/nanospheres, nanocrystals, liposomes, nano lipid carriers/solid lipid nanoparticles, nanosponges and dendrimers based on biomimetics for targeted delivery of the drug. For instance, according to the review article "Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system" published in November 2022, the biological roles of cell membrane surface proteins endow nanoparticles with several functions, such as immune escape, long circulation time, and targeted delivery; therefore, these proteins are being extensively used in the fields of drug delivery. According to the same source, in the biomimetic approach, the erythrocytes membrane is used to coat polymeric nanoparticles in order to reduce macrophage uptake and systemic clearance.

Furthermore, the surge in the prevalence of cardiac diseases propels the demand for bioengineering technology to grow human replacement tissues as next-generation implants such as LifeMatrix tissues drive the growth of the medical biomimetics market. For instance, according to the Centers for Disease Control and Prevention (CDC) 2022, about 697,000 people in the U.S. died from heart disease in 2020. According to the same source, every year, about 805,000 people in the U.S. have a heart attack. Out of these 805,000 people, 605,000 people have a first heart attack and 200,000 happen to people who have already had a heart attack.

In addition, the rise in the trend of biomimetics products, an increase in awareness regarding biomimetics product, an increase in the number of clinical trials of biomimetics product, rise in the discovery & development of effective medical biomimetics product, drives the growth of the medical biomimetics market. For instance, in July 2020, CorNeat KPro, the first synthetic cornea that bio-integrated with the eye wall, received approval to begin a clinical trial at Beilinson Hospital, Israel. The CorNeat KPro implant is designed to replace deformed, scarred, or opacified corneas and is expected to fully rehabilitate the vision of corneally blind patients immediately following implantation. The device's lens, which provides optical quality equivalent to a perfect cornea, integrates with resident ocular tissue using a unique and patented synthetic non-degradable nano-fabric skirt placed under the conjunctiva.

However, the high costs of medical biomimetics, health risks, and complications associated with medical biomimetics are expected to hamper the medical biomimetics market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for medical biomimetics product manufacturers in the future.

Furthermore, the healthcare business is projected to witness growth, owing to a rise in the technological advancements in orthopedic products, a rise in research in the bioengineering field, and the development of advanced medical biomimetics boosting the growth of the medical biomimetics market.

The medical biomimetics market is segmented on the basis of disease type, application, and region. On the basis of disease type, the market is classified into cardiovascular, orthopedic, ophthalmology, dental, and others. On the basis of application, the market is classified into wound healing, tissue engineering, drug delivery, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are: AVINENT Science and Technology, BioHorizons, Blatchford Limited, CorNeat Vision, Curasan, Inc., Keystone Dental Group, Osteopore International Pte Ltd, Otsuka Medical Devices group (Veryan Medical Limited), Swedish Biomimetics 3000 ApS, and Zimmer Biomet.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the medical biomimetics market analysis from 2021 to 2031 to identify the prevailing medical biomimetics market opportunities.
  • Market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • An in-depth analysis of the medical biomimetics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes an analysis of the regional as well as global medical biomimetics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

  • Ophthalmology
  • Cardiovascular
  • Orthopedic
  • Dental
  • Others

By Application

  • Wound Healing
  • Tissue Engineering
  • Drug Delivery
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • AVINENT Science and Technology
  • CorNeat Vision
  • Osteopore International Pte Ltd
  • Curasan, inc.
  • Biohorizons
  • Otsuka Medical Devices Co., Ltd.
  • Swedish Biomimetics 3000 ApS
  • Keystone Dental Group
  • Blatchford Limited
  • Zimmer Biomet Holding Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. High bargaining power of buyers
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low threat of new entrants
    • 3.3.5. Moderate intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence and incidence of chronic wounds
      • 3.4.1.2. Rise in prevalence of dental disease
      • 3.4.1.3. Rise in prevalence of heart disease
    • 3.4.2. Restraints
      • 3.4.2.1. Strict regulatory rules and high per-unit cost of production
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D and product launch
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MEDICAL BIOMIMETICS MARKET, BY DISEASE TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Cardiovascular
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Orthopedic
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Ophthalmology
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Dental
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: MEDICAL BIOMIMETICS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Wound Healing
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Tissue Engineering
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Drug Delivery
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: MEDICAL BIOMIMETICS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Disease Type
    • 6.2.3. Market size and forecast, by Application
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Disease Type
      • 6.2.4.1.3. Market size and forecast, by Application
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Disease Type
      • 6.2.4.2.3. Market size and forecast, by Application
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Disease Type
      • 6.2.4.3.3. Market size and forecast, by Application
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Disease Type
    • 6.3.3. Market size and forecast, by Application
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Disease Type
      • 6.3.4.1.3. Market size and forecast, by Application
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Disease Type
      • 6.3.4.2.3. Market size and forecast, by Application
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Disease Type
      • 6.3.4.3.3. Market size and forecast, by Application
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Disease Type
      • 6.3.4.4.3. Market size and forecast, by Application
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Disease Type
      • 6.3.4.5.3. Market size and forecast, by Application
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Disease Type
      • 6.3.4.6.3. Market size and forecast, by Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Disease Type
    • 6.4.3. Market size and forecast, by Application
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. China
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Disease Type
      • 6.4.4.1.3. Market size and forecast, by Application
      • 6.4.4.2. Japan
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Disease Type
      • 6.4.4.2.3. Market size and forecast, by Application
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Disease Type
      • 6.4.4.3.3. Market size and forecast, by Application
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Disease Type
      • 6.4.4.4.3. Market size and forecast, by Application
      • 6.4.4.5. Rest of Asia-Pacific
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Disease Type
      • 6.4.4.5.3. Market size and forecast, by Application
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Disease Type
    • 6.5.3. Market size and forecast, by Application
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Disease Type
      • 6.5.4.1.3. Market size and forecast, by Application
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Disease Type
      • 6.5.4.2.3. Market size and forecast, by Application
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Disease Type
      • 6.5.4.3.3. Market size and forecast, by Application
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Disease Type
      • 6.5.4.4.3. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2021

CHAPTER 8: COMPANY PROFILES

  • 8.1. Otsuka Medical Devices Co., Ltd.
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. AVINENT Science and Technology
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
  • 8.3. CorNeat Vision
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Key strategic moves and developments
  • 8.4. Swedish Biomimetics 3000 ApS
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
  • 8.5. Osteopore International Pte Ltd
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Curasan, inc.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
  • 8.7. Keystone Dental Group
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Key strategic moves and developments
  • 8.8. Zimmer Biomet Holding Inc.
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Biohorizons
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
  • 8.10. Blatchford Limited
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Key strategic moves and developments